Abbott Laboratories (NYSE:ABT) Updates FY23 Earnings Guidance
Abbott Laboratories (NYSE:ABT) Updates FY23 Earnings Guidance
Abbott Laboratories (NYSE:ABT – Get Rating) updated its FY23 earnings guidance on Wednesday. The company provided earnings per share guidance of $4.30-4.50 for the period, compared to the consensus earnings per share estimate of $4.45. Abbott Laboratories also updated its FY 2023 guidance to $4.30-$4.50 EPS.
周三,雅培(纽约证券交易所代码:ABT-GET Rating)更新了其23财年收益指引。该公司提供了4.30美元至4.50美元的每股收益指引,而市场普遍预期的每股收益为4.45美元。雅培还将其2023财年每股收益指引更新为4.30美元至4.50美元。
Analysts Set New Price Targets
分析师设定新的价格目标
A number of analysts recently issued reports on ABT shares. Stifel Nicolaus raised their price target on Abbott Laboratories from $110.00 to $125.00 and gave the stock a buy rating in a research report on Thursday. Royal Bank of Canada cut their target price on Abbott Laboratories from $132.00 to $126.00 and set an outperform rating on the stock in a research note on Thursday, October 20th. Jefferies Financial Group initiated coverage on Abbott Laboratories in a research note on Wednesday, October 12th. They set a hold rating and a $110.00 price target on the stock. Morgan Stanley boosted their price target on Abbott Laboratories from $117.00 to $133.00 and gave the stock an overweight rating in a research note on Friday, January 6th. Finally, Wells Fargo & Company dropped their price target on Abbott Laboratories from $150.00 to $140.00 and set an overweight rating on the stock in a research note on Monday, October 10th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, Abbott Laboratories presently has a consensus rating of Moderate Buy and a consensus target price of $125.63.
多位分析师最近发布了有关ABT股票的报告。周四,Stifel Nicolaus在一份研究报告中将雅培的目标价从110.00美元上调至125.00美元,并给予该股买入评级。10月20日,周四,加拿大皇家银行在一份研究报告中将雅培的目标价从132.00美元下调至126.00美元,并对该股设定了表现优于大盘的评级。杰富瑞金融集团在10月12日星期三的一份研究报告中发起了对雅培的报道。他们为该股设定了持有评级和110.00美元的目标价。摩根士丹利将雅培的目标价从117.00美元上调至133.00美元,并在1月6日星期五的一份研究报告中给出了该股的增持评级。最后,富国银行将雅培的目标价从150.00美元下调至140.00美元,并在10月10日星期一的一份研究报告中对该股设定了增持评级。一位研究分析师对该股的评级为卖出,3位分析师给出了持有评级,12位分析师给出了该公司的买入评级。根据MarketBeat的数据,雅培目前的共识评级为适度买入,共识目标价为125.63美元。
Abbott Laboratories Trading Down 1.0 %
雅培股价下跌1.0%
Shares of NYSE:ABT opened at $109.95 on Friday. The company has a market capitalization of $191.71 billion, a PE ratio of 28.12, a PEG ratio of 5.06 and a beta of 0.69. Abbott Laboratories has a 12-month low of $93.25 and a 12-month high of $130.93. The business has a 50 day moving average of $109.07 and a two-hundred day moving average of $105.86. The company has a current ratio of 1.86, a quick ratio of 1.43 and a debt-to-equity ratio of 0.43.
纽约证券交易所股票代码:ABT上周五开盘报109.95美元。该公司市值为1,917.1亿美元,市盈率为28.12倍,聚乙醇率为5.06倍,贝塔系数为0.69。雅培的12个月低点为93.25美元,12个月高位为130.93美元。该业务的50日移动均线切入位在109.07美元,200日移动均线切入位在105.86美元。该公司的流动比率为1.86,速动比率为1.43,债务权益比率为0.43。
Abbott Laboratories Increases Dividend
雅培增加分红
The company also recently declared a quarterly dividend, which will be paid on Wednesday, February 15th. Investors of record on Friday, January 13th will be given a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a dividend yield of 1.86%. This is a boost from Abbott Laboratories's previous quarterly dividend of $0.47. The ex-dividend date is Thursday, January 12th. Abbott Laboratories's payout ratio is presently 52.17%.
该公司最近还宣布了季度股息,将于2月15日(星期三)支付。1月13日(星期五)登记在册的投资者将获得每股0.51美元的股息。这意味着年化股息为2.04美元,股息收益率为1.86%。这是对雅培之前季度派息0.47美元的提振。除息日期为1月12日星期四。雅培目前的派息率为52.17%。
Insider Buying and Selling
内幕买卖
In related news, EVP John F. Ginascol sold 11,000 shares of the business's stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $112.32, for a total transaction of $1,235,520.00. Following the completion of the sale, the executive vice president now directly owns 111,912 shares in the company, valued at $12,569,955.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.52% of the stock is owned by company insiders.
在相关新闻中,执行副总裁约翰·F·吉纳斯科在12月13日星期二的一次交易中出售了11,000股该公司的股票。股票以112.32美元的平均价格出售,总成交金额为1235520.00美元。出售完成后,执行副总裁总裁现在直接持有该公司111,912股股份,价值12,569,955.84美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过美国证券交易委员会网站。0.52%的股份由公司内部人士持有。
Institutional Trading of Abbott Laboratories
雅培的机构交易
Large investors have recently added to or reduced their stakes in the stock. MQS Management LLC purchased a new stake in Abbott Laboratories in the 3rd quarter valued at $702,000. Mirabella Financial Services LLP acquired a new position in shares of Abbott Laboratories in the 1st quarter valued at $664,000. Summit Financial Group Inc. lifted its stake in shares of Abbott Laboratories by 5.0% in the 3rd quarter. Summit Financial Group Inc. now owns 6,393 shares of the healthcare product maker's stock valued at $618,000 after purchasing an additional 303 shares during the last quarter. West Michigan Advisors LLC lifted its stake in shares of Abbott Laboratories by 11.0% in the 1st quarter. West Michigan Advisors LLC now owns 4,637 shares of the healthcare product maker's stock valued at $549,000 after purchasing an additional 461 shares during the last quarter. Finally, Balyasny Asset Management LLC acquired a new position in shares of Abbott Laboratories in the 3rd quarter valued at $513,000. 72.93% of the stock is currently owned by hedge funds and other institutional investors.
大型投资者最近增持或减持了该股。MQS Management LLC在第三季度购买了雅培的新股份,价值70.2万美元。米拉贝拉金融服务有限责任公司在第一季度收购了雅培的新股票头寸,价值66.4万美元。顶峰金融集团在第三季度增持了雅培的股份5.0%。顶峰金融集团(Summit Financial Group Inc.)现在持有这家医疗保健产品制造商6,393股股票,价值61.8万美元,此前该公司在上个季度又购买了303股。西密歇根顾问有限责任公司在第一季度增持了雅培11.0%的股份。西密歇根顾问有限责任公司现在拥有4637股保健品制造商的股票,价值54.9万美元,在上个季度又购买了461股。最后,Balyasny Asset Management LLC在第三季度收购了雅培的新头寸,价值513,000美元。72.93%的股票目前由对冲基金和其他机构投资者持有。
Abbott Laboratories Company Profile
雅培公司简介
(Get Rating)
(获取评级)
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products.
雅培致力于发现、开发、制造和销售广泛而多样化的保健品系列。它通过以下细分市场运作:成熟的医药产品、营养产品、诊断产品和医疗设备。已建立的医药产品部门是指一系列品牌仿制药产品的国际销售。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Abbott Laboratories (ABT)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 免费获取斯托克新闻网关于雅培的研究报告(ABT)
- 市场回顾周-1/23-1/27
- 为什么Lucid在一天内飙升了近100%
- 利用这些铁路股票实现增长和收入
- ASML预计今年芯片需求回升,提振销售观点
- KLA公司:在动荡不安的半市场中站稳脚跟
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
接受《雅培日报》的新闻和评级-在下面输入您的电子邮件地址,即可通过MarketBeat.com的免费每日电子邮件时事通讯接收对雅培及相关公司的最新新闻和分析师评级的每日摘要。